探究阿托伐他汀钙联合替格瑞洛应用于冠心病高脂血症患者的临床疗效以及对血清中细胞因子的影响。

选取2018年4月到2019年3月在东莞市人民医院接受诊治的冠心病高血脂症患者139例，随机分为对照组和观察组，对照组给予阿托伐他汀钙联合氯吡格雷治疗，而观察组给予阿托伐他汀钙联合替格瑞洛治疗，持续12周，记录治疗前后两组患者心绞痛发病频率和持续时间，记录两组的总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C），以及血清同型半胱氨酸（Hcy）、超敏C反应蛋白（hs-CRP）和人血管内皮细胞生长因子（VEGF）的含量变化，观察两组患者的不良反应的情况。

观察组在干预12周后的心绞痛发作频率和发作持续时间显著低于对照组，差异具有统计学意义（P<0.05）。两组患者干预前TC、HDL-C、LDL-C、TG以及血清中Hcy、hs-CRP和VEGF的含量无统计学差异（P>0.05），两组患者治疗后的TC、HDL-C、LDL-C、TG均显著改善（P<0.05），血清中Hcy、hs-CRP的含量显著降低（P<0.05），而VEGF的含量则明显升高（P<0.05）；且与对照组相比，观察组患者治疗后血清中Hcy、hs-CRP水平显著下降，而VEGF的水平显著升高，其差异具有统计学意义（P<0.05）。

阿托伐他汀钙联合替格瑞洛能有效控制冠心病高血脂症患者的血脂水平，抑制血清中Hcy、hs-CRP的含量，提高VEGF的表达水平，效果优于阿托伐他汀钙联合氯吡格雷方案。

To explore the clinical efficacy of atorvastatin calcium combined with ticagrelor in patients with coronary heart disease and hyperlipidemia and its effect on serum cytokines.

139 patients with coronary heart disease and hyperlipidemia who were diagnosed and treated in our hospital from April 2018 to March 2019 were randomly divided into control group and observation group. The control group was treated with atorvastatin calcium combined with clopidogrel. The observation group was given atorvastatin calcium combined with ticagrelor for 12 weeks. The frequency and duration of angina pectoris in the two groups before and after treatment were recorded, and the TC, TG, HDL-C, LDL-C, and Serum Hcy, hs-CRP and VEGF levels were changed, and the adverse reactions of the two groups of patients were observed.

The frequency and duration of angina pectoris in the observation group after 12 weeks of intervention were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the levels of TC, HDL-C, LDL-C, TG and serum Hcy, hs-CRP and VEGF before intervention between the two groups of patients (P>0.05). The TC, HDL-C, LDL-C and TG were significantly improved (P<0.05), the content of Hcy and hs-CRP in the serum was significantly reduced (P<0.05), while the content of VEGF was significantly increased (P<0.05); and compared with the control group Compared with the observation group, the serum Hcy and hs-CRP levels decreased significantly after treatment, while the VEGF level increased significantly, and the difference was statistically significant (P<0.05).

Atorvastatin calcium combined with ticagrelor can effectively control the blood lipid level of patients with coronary heart disease hyperlipidemia, inhibit the content of Hcy and hs-CRP in the serum, and increase the expression level of VEGF. The effect is better than that of atorvastatin calcium. Combined clopidogrel regimen.